MENU

FDA Weekly Report 9/9-15

Members: skip the article and download now
TROY INTELLIGENCE FDA Weekly Briefing / EN Edition
DOC. NO. TI-EN-2026-W38-0909
ISSUE 38-0909  /  2026-09-09 — 2026-09-15

FDA Weekly Report 9/9–9/15: 3 new drug approvals (2 new molecular entities: ISEMBYLD, PIXCLARA)

Drug coverage is FDA approval dates 2026-09-09 to 2026-09-15; 4 efficacy supplements and 11 generic (ANDA) approvals were also recorded.

Reporting period 2026-09-09 to 2026-09-15 (FDA posting-date basis)   Published 2026-09-27

DISCLOSURE
Partial release

Between 2026-09-09 and 2026-09-15, FDA approved 3 new drug applications (NDA/BLA), including 2 new molecular entities, plus 4 efficacy supplements and 11 generics (ANDA). Medical devices cover decision dates 2026-08-29 to 2026-09-06: 69 510(k) clearances, 1 De Novo classification, and 0 original PMA approvals. Drug recalls cover FDA posting dates 2026-09-03 to 2026-09-09 (34 recalls); 1 notable Warning Letter.

This page excerpts a portion of the facts from the full briefing sent weekly to paid members. The complete dataset, violation details, and bilingual FDA approval-letter translations are member-only, as noted in the “Full edition” section below.

TELEMETRY W38-0909 SUMMARY
2
New Molecular Entities (NME)
3
New drug approvals (NDA/BLA)
11
Generic approvals (ANDA)
0
Device PMA, original (08-29–09-06)
34
Drug recalls (posted 09-03–09-09)
69
510(k) clearances (08-29–09-06; plus 1 De Novo)
1
Warning Letters (notable)
6
FDA guidance/notices

Featured briefing — 4 items

NME

SCHOLAR ROCK INC — ISEMBYLD (APITEGROMAB-MSTN)

Approved as a new molecular entity on 2026-09-11 (BLA761463).

NME

TELIX PHARMACEUTICALS US INC — PIXCLARA (FLORETYROSINE F 18)

Approved as a new molecular entity on 2026-09-11 (NDA218592).

ASIA DRUG

STRIDES PHARMA — MILNACIPRAN HYDROCHLORIDE

India-based sponsor; approved as a generic (ANDA) on 2026-09-15 (ANDA207399).

ASIA DEVICE

Hironic Co., Ltd. — SYNERJET PRO (SP-1003); InPhiuse (SP-1003); WOWJET (SP-1003)

South Korea-based applicant; 510(k) clearance decided 2026-08-31 (K260387). Device coverage: 2026-08-29 to 2026-09-06.

PERFORATION — members-only section begins here

What the full edition includes

510(k)/De Novo/PMA decisions — 4 of 70 disclosed

DeviceApplicantTypeDecision date
SYNERJET PRO (SP-1003); InPhiuse (SP-1003); WOWJET (SP-1003)Hironic Co., Ltd.510(k)2026-08-31
Facial Beauty Device (Facial Mask LED Beauty Device A-901; Facial LED & EMS Beauty Device A-902; Facial Mask LED & EMS Beauty Device A-907)Kam Yuen Plastic Products, Ltd.510(k)2026-08-31
Automatic Digital Blood Pressure monitor (LD-526)Honsun (Nantong) Co., Ltd.510(k)2026-08-31
Flowable Restorative Material (KP-Flow LF, KP-Flow MF, KP-Flow HF)Guilin Kevin Peter Technology Co., Ltd.510(k)2026-08-31
MEMBERS ONLY
66 more not shown
  • All 34 drug recalls — product, reason and classification for every recall
  • Full text of 1 Warning Letters — issuing company, cited regulations, and issuing office
  • Bilingual FDA approval letters (PDF) — original text and translation side by side, with implications for competitors
  • Full FDA dataset (Excel) — structured data including product code, review time, and applicant

On our verification process

01

No claim without a source

The AI is not permitted to generate claims absent from primary-source text. Where extraction fails, the report states so explicitly rather than filling the gap.

02

Automated cross-check after generation

Generated text is mechanically checked against the primary source; unsupported statements are automatically flagged and removed.

03

Key items verified against the original letter

New drug approvals and major efficacy supplements are checked against the actual FDA approval letter before being described.

Who reads this

Regulatory Affairs — track competitor approvals and label changes weeklyQA / Quality — monitor recall and Warning Letter trendsR&D — follow competitor pipeline approvals and indication expansionsBusiness Development — spot licensing opportunities and competitive moves earlyCorporate Strategy — quantify industry trends for internal reporting

Plans

INDIVIDUAL
$89/mo
Individual PDF + Excel + Letter Collection
Select This Plan
TEAM
$350/mo
or $2,980/yr · shareable within team
Select This PlanSubscribe annually
CORPORATE
$8,900/yr
Company-wide sharing
Select This Plan

This report is a compilation and summary of information publicly announced by the FDA. It does not recommend, endorse, or make any representation regarding the efficacy or safety of any specific drug or medical device, nor does it constitute investment, legal, or medical advice.

TROY INTELLIGENCE — FDA WEEKLY BRIEFING / EN EDITION
目次